During COVID-19 outbreak, research regarding whether Lianhua Qingwen (LHQW) was effective and safe in treating COVID-19 cases reported a markedly shorter recovery time, probably associated with the suppressed IL-6, IP-10, and TNF-α expression, whereas promoted inflammatory cell infiltration.69,70 Yang et al. revealed that LHQW attenuated lipopolysaccharide (LPS)-mediated ALI, with LHQW at a medium-dose exhibiting the best efficacy. The gene discussed is IL6; the disease is COVID-19.